CHGCY लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 01:29):

Stats
आज की मात्रा	76 389.00
औसत मात्रा	183 993
बाजार मूल्य	54.17B
EPS	$0 ( 2024-04-25 )
अगली कमाई की तारीख	( $0 ) 2024-07-25
Last Dividend	$0.189 ( 2021-12-29 )
Next Dividend	$0 ( N/A )
P/E	26.13
ATR14	$0.0120 (0.07%)

मात्रा सहसंबंध

लंबा: 0.07 (neutral)

छोटा: 0.33 (neutral)

Signal:(55.489) Neutral

Chugai Pharmaceutical सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

Chugai Pharmaceutical सहसंबंध - मुद्रा/वस्त्र

0.41
( neutral )

0.00
( neutral )

-0.66
( moderate negative )

-0.30
( neutral )

Chugai Pharmaceutical वित्तीय

Annual	2023
राजस्व:	$1 111.37B
सकल लाभ:	$693.01B (62.36 %)
EPS:	$197.83

FY	2023
राजस्व:	$1 111.37B
सकल लाभ:	$693.01B (62.36 %)
EPS:	$197.83

FY	2022
राजस्व:	$1 259.95B
सकल लाभ:	$783.70B (62.20 %)
EPS:	$227.64

FY	2021
राजस्व:	$999.76B
सकल लाभ:	$661.61B (66.18 %)
EPS:	$92.15

Financial Reports:

No articles found.

Chugai Pharmaceutical Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Chugai Pharmaceutical Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 8.15 - good (81.48%) | Divividend Growth Potential Score: 5.60 - Stable (12.07%)

Information

First Dividend	$0.138	2020-12-29
Last Dividend	$0.189	2021-12-29
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.463	--
Avg. Dividend % Per Year	0.00%	--
Score	3.09	--
Div. Sustainability Score	8.15
Div.Growth Potential Score	5.60
Div. Directional Score	6.88	--

Next Divdend (Est)
(2024-09-27)

$0 Estimate 0.00 %

Dividend Stability

0.05 Very Bad

Dividend Score

3.09

Pay Frequency

Semi-Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for OTC

Symbol	Title	Last dividend	Frequency	Yearly Dividend
RWCB	Ex Dividend Knight	2023-07-28	Quarterly	0.00%
FFDF	Ex Dividend Knight	2023-08-01	Quarterly	0.00%
WTKWY	Ex Dividend Knight	2023-08-29	Annually	0.00%
MAAL	Ex Dividend Knight	2023-09-22	Quarterly	0.00%
CKHUY	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
SOBS	Ex Dividend Knight	2023-06-29	Quarterly	0.00%
HALMY	Ex Dividend Knight	2023-07-14	Semi-Annually	0.00%
AILLM	Ex Dividend Knight	2023-07-14	Quarterly	0.00%
NHYDY	Ex Dividend Knight	2023-05-11	Annually	0.00%
CRARY	Ex Dividend Junior	2023-05-25	Sporadic	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.315	1.500	3.70	5.55	[0 - 0.5]
returnOnAssetsTTM	0.172	1.200	4.27	5.12	[0 - 0.3]
returnOnEquityTTM	0.207	1.500	8.81	10.00	[0.1 - 1]
payoutRatioTTM	0.402	-1.000	5.98	-5.98	[0 - 1]
currentRatioTTM	5.53	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.21	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	1.937	1.500	0.351	0.526	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	16 118	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.677	1.000	2.05	2.05	[0.2 - 0.8]
operatingProfitMarginTTM	0.420	1.000	3.60	3.60	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0.546	0.800	9.69	7.75	[0.5 - 2]
Total Score				8.15

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	12.70	1.000	8.82	0	[1 - 100]
returnOnEquityTTM	0.207	2.50	9.24	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	197.34	2.00	10.00	10.00	[0 - 30]
dividendYielPercentageTTM	0.00876	1.500	9.78	0	[0 - 0.4]
operatingCashFlowPerShareTTM	233.57	2.00	10.00	10.00	[0 - 30]
payoutRatioTTM	0.402	1.500	5.98	-5.98	[0 - 1]
pegRatioTTM	0.00187	1.500	-3.32	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.371	1.000	3.23	0	[0.1 - 0.5]
Total Score				5.60

Chugai Pharmaceutical

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.